SCHEMBL2986735

SCHEMBL2986735

Cc1cc(NC[C@@H](O)CNC(=O)c2ccc(Cl)s2)c(F)cc1N1CCCCC1=O

nearest known ligand 0.56

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
F10 P00742 20/20 0.56
F2 P00734 4/20 0.50
F9 P00740 2/20 0.47
PLG P00747 2/20 0.47
PLAT P00750 2/20 0.47
KLKB1 P03952 2/20 0.47
PRSS1 P07477 2/20 0.47
PRSS2 P07478 2/20 0.47
PRSS3 P35030 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2986738 1.00 F10 (0.56) F10F2F9PLGPLAT
SCHEMBL3678497 0.88 F10 (0.45) F10F2F9PLGPLAT
SCHEMBL2989829 0.87 F10 (0.58) F10F2
SCHEMBL2989830 0.87 F10 (0.58) F10F2
SCHEMBL2985010 0.86 F10 (0.61) F10F2
SCHEMBL2985012 0.86 F10 (0.61) F10F2
SCHEMBL76968 0.79 F10 (0.51) F10F2F9PLGPLAT
SCHEMBL78680 0.78 F10 (0.54) F10F2F9PLGPLAT
SCHEMBL2993498 0.78 F10 (0.78) F10
SCHEMBL2992839 0.76 F10 (0.51) F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100184767-A1 SUBSTITUTED OXAZOLIDINONES AND USE THEREOF ROHRIG SUSANNE 2010-07-22 US disclosed
US-20100184767-A1 SUBSTITUTED OXAZOLIDINONES AND USE THEREOF ROHRIG SUSANNE 2010-07-22 US disclosed
US-20100184767-A1 SUBSTITUTED OXAZOLIDINONES AND USE THEREOF ROHRIG SUSANNE 2010-07-22 US disclosed
WO-2008155034-A1 SUBSTITUTED OXAZOLIDINONES AND THE USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184767-A1 SUBSTITUTED OXAZOLIDINONES AND USE THEREOF XDH, OXA1L, PPOX F10 391/4885F2 39/4885F9 697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.